Healrna's mRNA2.0 R & D Ushered in a New Chapter for the Industry

" I-RNA 4th Nucleic Acid Drug Industry Deep Dive Summit "

Recently, the "I-RNA 4th Nucleic Acid Drug Industry Deep Dive Summit" was held in Suzhou.

This conference focused on new technologies and core challenges in nucleic acid drug development, addressing the hurdles in nucleic acid drug delivery, analyzing the latest advancements in process development, and accelerating the industrialization and commercialization processes. It aimed to strengthen the nucleic acid drug supply chain and drive the entire industry forward. The event invited numerous experts and industry leaders to participate. Through three forums and six thematic discussions, the conference facilitated in-depth exchanges on innovative R&D and progress in mRNA vaccines and drugs, technical challenges in nucleic acid drug delivery systems and modifications, as well as the latest advancements and frontier explorations in small nucleic acid drugs.

Dr. Chen Zhong from Healrna was invited to share the company's latest research achievements and progress during the session on mRNA vaccine and drug process technology and quality control.

#Healrna's mRNA 2.0 R&D and Industrialization#

(Image: Dr. Chen Zhong)

Dr. Chen Zhong, Vice President of Healrna, delivered a presentation titled "R&D and Industrialization of Healrna's mRNA 2.0," sharing the latest advancements in the company's three major technology platforms—the high-throughput intelligent mRNA design and synthesis platform, the nucleic acid delivery carrier CLS platform, and the Genmax nucleic acid drug production platform—as well as the latest research findings on veterinary mRNA vaccines in target animals (DOI: 10.1128/mbio.02958-23).

Biotechnology is currently one of the most dynamic technological fields, and this report sparked significant interest and attention from both domestic and international peers, offering valuable insights into the development of domestic mRNA vaccines in the post-pandemic era.

In the concluding discussion, Dr. Chen Zhong addressed the challenges and obstacles currently faced by the biotechnology industry, expressing hope that this symposium would further promote innovation, collaboration, and the exchange of new ideas and perspectives in the field of biotechnology.

# About Healrna#

Healrna is a high-tech Biotech company specializing in the research and industrialization of nucleic acid drugs. The company's operations span mRNA drug R&D and regulatory submissions, clinical trial design, data analysis, and industrialization. Leveraging its proprietary next-generation mRNA delivery system—the cell-like membrane platform—Healrna is developing efficient vaccines for infectious diseases, cancer vaccines, cell therapies, and protein replacement therapies.

Currently, the company has established a comprehensive "trinity" nucleic acid drug R&D and production platform, including the innovative nucleic acid delivery carrier CLS (Cell-Like System) development platform, the Genmax nucleic acid drug production platform, and a high-throughput, intelligent mRNA design and synthesis platform. HuiLiao Bio is committed to advancing the development of next-generation vaccines and therapeutic drugs.